We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+4.81%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$603M
AUM Growth
-$85.4M
(-12%)
Cap. Flow
-$60.6M
Cap. Flow
% of AUM
-10.04%
Top 10 Holdings %
Top 10 Hldgs %
45.31%
Holding
86
New
11
Increased
4
Reduced
19
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$25.6M |
| 2 |
RXDX
Ignyta, Inc.
RXDX
|
+$12.2M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$12M |
| 4 |
Omeros
OMER
|
+$9.6M |
| 5 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$8.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Theravance Biopharma
TBPH
|
+$18.3M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$13.9M |
| 3 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
+$12.7M |
| 4 |
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
|
+$10.1M |
| 5 |
CBPO
China Biologic Products Holdings, Inc.
CBPO
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
1
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $50.6M | 8.38% |
900,000
+300,000
| +50% | +$12M |
|
|
2
Theravance Biopharma
TBPH
$873M
| $37.8M | 6.27% |
950,000
-475,000
| -33% | -$18.3M |
|
|
BLUE
3
DELISTED
bluebird bio
BLUE
| $28.9M | 4.79% |
+21,230
| New | +$25.6M |
|
|
QTNT
4
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $26.1M | 4.33% |
88,725
+16,250
| +22% | +$4.58M |
|
|
5
Omeros
OMER
$863M
| $25.9M | 4.29% |
1,300,000
+550,000
| +73% | +$9.6M |
|
|
LKFT
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
| $22.9M | 3.8% |
300,000
| – | – |
|
|
JUNO
7
DELISTED
Juno Therapeutics, Inc.
JUNO
| $22.4M | 3.72% |
750,000
+100,000
| +15% | +$2.47M |
|
|
NVRO
8
DELISTED
NEVRO CORP.
NVRO
| $20.1M | 3.33% |
270,000
-80,000
| -23% | -$6.41M |
|
9
Aclaris Therapeutics
ACRS
$743M
| $19.5M | 3.24% |
720,000
-80,000
| -10% | -$2.17M |
|
10
AnaptysBio
ANAB
$1.63B
| $19.1M | 3.17% |
799,469
-96,157
| -11% | -$2.42M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $18.6M | 3.09% |
367,900
-232,100
| -39% | -$9.86M |
|
|
KA
12
DELISTED
Kineta, Inc. Common Stock
KA
| $17.8M | 2.95% |
27,172
| – | – |
|
|
CLSD
13
DELISTED
Clearside Biomedical
CLSD
| $17.7M | 2.93% |
129,392
| – | – |
|
14
Minerva Neurosciences
NERV
$187M
| $17.7M | 2.93% |
249,677
-38,811
| -13% | -$2.51M |
|
|
EGRX
15
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $15.8M | 2.62% |
200,000
| – | – |
|
|
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
| $15.5M | 2.57% |
+1,500,000
| New | +$12.2M |
|
|
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $13.1M | 2.17% |
1,000,000
-130,000
| -12% | -$1.71M |
|
|
MTVA
18
MetaVia Inc
MTVA
$7.44M
| $12.3M | 2.04% |
14
| – | – |
|
19
Neurocrine Biosciences
NBIX
$18.7B
| $11.5M | 1.91% |
250,000
-50,000
| -17% | -$2.43M |
|
|
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
| $10.3M | 1.71% |
900,000
-198,205
| -18% | -$3.66M |
|
21
Alnylam Pharmaceuticals
ALNY
$27.4B
| $9.97M | 1.65% |
+125,000
| New | +$7.99M |
|
22
Coherus Oncology
CHRS
$227M
| $8.9M | 1.48% |
620,300
| – | – |
|
|
GTHX
23
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $8.37M | 1.39% |
+479,986
| New | +$8.4M |
|
24
Heron Therapeutics
HRTX
$94.1M
| $7.89M | 1.31% |
570,000
-630,000
| -53% | -$9.12M |
|
|
ARRY
25
DELISTED
Array Biopharma Inc
ARRY
| $7.53M | 1.25% |
900,000
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Cormorant Asset Management held 86 positions worth $603M, down 12% from $689M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Cormorant Asset Management withdrew a net $60.6M in Q2 2017, closing 15 positions and reducing 19 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $13.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in bluebird bio worth $28.9M.
- Cormorant Asset Management's largest Q2 2017 buy was bluebird bio: 21,230 shares worth $28.9M.
- Cormorant Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2017, an estimated $12M increase.
- Cormorant Asset Management's biggest Q2 2017 reduction was Theravance Biopharma, cutting an estimated $18.3M.
- Cormorant Asset Management fully exited Corbus Pharmaceuticals in Q2 2017, selling an estimated $13.9M.
- Cormorant Asset Management's ten largest holdings make up 45% of its $603M portfolio in Q2 2017.
- Cormorant Asset Management opened 11 new positions and closed 15 in Q2 2017.
- Cormorant Asset Management's portfolio value fell 12% quarter-over-quarter to $603M.
Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.